News | July 21, 2025
Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
These medicines are essential in preventing RhD immunisation during pregnancy
The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
Subscribe To Our Newsletter & Stay Updated
